OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 03:54:53 2024-05-22 am EDT | ||
| 3.93 EUR | -0.25% |
|
| Current month | +2.60% | ||
| 1 month | +15.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 3.93 | -0.25% |
| 24-05-21 | 3.94 | +2.60% |
| 24-05-20 | 3.84 | +1.59% |
| 24-05-17 | 3.78 | +0.27% |
| 24-05-16 | 3.77 | +1.07% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 03:54 am EDT
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SF7KAU |
| ISIN | DE000SF7KAU4 |
| Date issued | 2021-08-02 |
| Strike | 85.23 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.12 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.95 € |
|---|---|
| Lowest since issue | 0.62 € |
| Spread | 0.03 € |
| Spread % | 0.76% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.27
USD
Average target price
53.19
USD
Spread / Average Target
+25.84%
- Stock Market
- Certificates
- Certificat